Qilu Pharmaceutical 4 generic drug Aripitan first imitation was approved immediately.

Recently, Qilu Pharmaceutical 4 generic arigitan capsule listing application (acceptance number CYHS1800538, 539) in the NMPA status changed to "in approval", which means that the first domestic Arigitan capsule was approved at that timeaprepitant, a neurokinin-1 (NK-1) receptor blocker developed by Mersadon, can selectively block and bind to NK-1 receptors to suppress vomiting caused by chemotherapy drugsThe drug is the world's first approved NK-1 receptor antagonist antidote antivomit drug, and the first chinese-listed pitan-type drug, is the prevention of highly vomiting anti-tumor chemotherapy in the initial, repeated treatment process of acute and late-onset nausea and vomiting drugsIn March 2003, the original Research Aripitan was approved by the FDA, the product is called Emend, is currently listed in more than 90 countries and regions around the worldEmend is reported to have global sales of $522 million in 2018In September 2013, Aripitan capsules were approved in China, the product is named Yimei, according to the public database, 2018 in the domestic key provinces and cities public hospital terminal Yimei sales of 74.78 million yuanAt present, in the domestic Qilu Pharmaceutical, Zhengda Tianqing and Nanjing Zhengda Tianqing have been submitted according to 4 types of generic drugs to submit the listing application, in addition, Grand Mark Priority has also submitted the import application of Aripitan capsulesBased on the current progress of the review, Qilu Pharmaceuticals will take the lead in breaking through and taking the first generic of the Aripitan capsulethe first half of 2020, Qilu Pharmaceuticals can be said to be one of the big winners of generic drugs approved, according to the data of the pharmaceutical Rubik's Cube a total of 10 generic drugs were approved, unfortunately, are not the first imitation varieties, it is worth mentioning that Qilu Pharmaceuticals is the big winner of the consistency evaluation in the first half of 2020, a total of 12 drugs through consistency evaluation, of which injection sizzle, capestabin tablets, Pribarin capsules, leflunomettablets, isimetin tablets, osalliplatin injections and cephalosporine particles 7 varieties are the first to pass the consistency evaluation